Friday, November 1st, 2019

11th Annual North Carolina Research Triangle Pulmonary Hypertension Symposium

Durham Convention Center
301 West Morgan Street
Durham, North Carolina 27701
Registration
Online registration and additional meeting information can be found at bit.ly/PulmonaryHTN2019

Registration fees
$195: MDs and DOs
$60: Non-Physician Clinicians, Allied Health, Residents, and Fellows
$195: Industry representatives
Registration fees include all symposium materials, breakfast, lunch and breaks.

Cancellation policy
All cancellation requests must be submitted in writing to Christy Darnell via email (christy.darnell@duke.edu). In the event that the program is cancelled or postponed, we will not be responsible for any travel costs or expenses, including cancellation/ change penalties assessed by airlines, travel agencies, or hotels.

After the event
To complete all course requirements and claim continuing education credits, please do the following:
- Complete the course evaluation.
- Attest to your hours of completion.
- Download your certificate.

Event contact
Christy Darnell
Duke Heart Center
Phone: 919-613-0988
Email: christy.darnell@duke.edu

Accommodations
A block of rooms has been reserved at the Durham Marriott City Center, 201 Foster Street, Durham, NC 27701. Rooms are $149 per night, plus applicable taxes. The room block will be held until Tuesday, October 1, 2019 but may sell out prior to this date. To reserve your room at the conference rate, please call 1-800-228-9290 or 919-768-6000 and reference the 11th Annual NC Research Triangle Pulmonary Hypertension Symposium. Reservations may also be made online at tinyurl.com/PulmonaryHTN2019-hotel

Joint accreditation statement
This activity has been planned and implemented by the Duke University Health System Department of Clinical Education & Professional Development for the advancement of patient care. In support of improving patient care, the Duke University Health System Department of Clinical Education & Professional Development is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACME), to provide continuing education for the healthcare team.

Category 1: Duke University Health System Department of Clinical Education and Professional Development designates this activity for a maximum of 6.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nurse CE: Duke University Health System Department of Clinical Education and Professional Development designates this activity for up to 6.5 credit hours for nurses. Nurses should claim only credit commensurate with the extent of their participation in this activity.

Pharmacists: Duke University Health System Department of Clinical Education and Professional Development designates this activity for a maximum of 6.5 ACPE credit hours. Universal Activity Numbers: JA0000655-0000-19-276-L01-P

Disclosure
The Duke University Health System Department of Clinical Education & Professional Development adheres to ACCME Essential Areas, Standards, and Policies regarding industry support of CE. Disclosure of the planning committee and faculty’s commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations.

Resolution of conflicts of interest
In accordance with the ACCME Standards for Commercial Support of CME, and prior to the planning and implementation of this CME activity, the Duke University Health System Department of Clinical Education & Professional Development will implement mechanisms to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

Disclaimer
The information provided at this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Special needs statement
The Duke University Health System Department of Clinical Education & Professional Development is committed to making its activities accessible to all individuals. If you need assistance or accommodation(s), please call and/or submit a description of your needs in writing to Christy Darnell via email (christy.darnell@duke.edu) or telephone (919-613-0988).

Commercial support acknowledgement
A complete list of supporters will be published in the course syllabus.
Faculty directors

H. James Ford, MD  
Associate Professor of Medicine  
Director, Pulmonary Hypertension Program  
Division of Pulmonary and Critical Care Medicine  
University of North Carolina at Chapel Hill

Terry Fortin, MD  
Associate Professor of Medicine  
Co-Director, Duke Pulmonary Vascular Disease Center  
Duke University Medical Center

Invited faculty

Talal I. Dahhan, MD, MSEd  
Assistant Professor of Medicine  
Pulmonary Vascular Disease Center  
Division of Pulmonary, Allergy and Critical Care Medicine  
Department of Medicine | Duke University

John Carroll Haney, MD, MPH  
Assistant Professor of Surgery  
Division of Cardiovascular and Thoracic Surgery  
Department of Surgery | Duke University

Anna Hemnes, MD  
Associate Professor of Medicine  
Assistant Director Pulmonary Vascular Center  
Division of Allergy, Pulmonary, and Critical Care Medicine  
Vanderbilt University Medical Center

Marc Humbert, MD, PhD  
Professor of Medicine  
University of South Paris  
Director, Department of Pulmonology and Intensive Care  
French Pulmonary Hypertension Reference Center  
Hôpital Bicêtre  
Assistance Publique Hôpitaux de Paris  
Le Kremlin Bicêtre, France

Sheila Krishnan, DO  
Assistant Professor of Medicine  
Pulmonary Hypertension Program  
University of North Carolina at Chapel Hill

Barbara LeVarge, MD  
Assistant Professor of Medicine  
Associate Director, Pulmonary Hypertension Program  
University of North Carolina at Chapel Hill

Kishan Parikh, MD  
Assistant Professor of Medicine  
Division of Cardiology  
Duke University Medical Center

Sudarshan Rajagopal, MD, PhD  
Assistant Professor of Medicine  
Co-Director, Duke Pulmonary Vascular Disease Center  
Division of Cardiology  
Duke University Medical Center

Lisa Rose-Jones, MD  
Assistant Professor of Medicine  
Pulmonary Hypertension Program  
University of North Carolina at Chapel Hill

Jordan Whitson, MD  
Medical Instructor in the Department of Medicine  
Division of Pulmonary, Allergy and Critical Care Medicine  
Duke University Medical Center
<table>
<thead>
<tr>
<th>TIME</th>
<th>TOPIC</th>
<th>SPEAKERS</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00–8:00 AM</td>
<td>Registration, Breakfast, and Exhibits</td>
<td></td>
</tr>
<tr>
<td>8:00–8:05 AM</td>
<td>Welcome and Introduction/Opening Remarks</td>
<td>H. James Ford, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Terry Fortin, MD</td>
</tr>
<tr>
<td>8:05–8:30 AM</td>
<td>Pulmonary Hypertension Overview 2019</td>
<td>Barbara LeVarge, MD</td>
</tr>
<tr>
<td>8:30–9:15 AM</td>
<td>PH Associated with Myeloproliferative and Hematologic Disorders</td>
<td>Marc Humbert, MD, PhD</td>
</tr>
<tr>
<td>9:15–9:50 AM</td>
<td>Assessing Surgical and Procedural Risk in PH</td>
<td>Lisa Rose-Jones, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jordan Whitson, MD</td>
</tr>
<tr>
<td>9:50–10:05 AM</td>
<td>Break/Exhibits</td>
<td></td>
</tr>
<tr>
<td>10:05–10:40 AM</td>
<td>Targeting the Right Ventricle in PAH</td>
<td>Sudarshan Rajagopal, MD, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sheila Krishnan, DO</td>
</tr>
<tr>
<td>10:40–11:20 AM</td>
<td>The Role of Cardiopulmonary Rehab in PH</td>
<td>Terry Fortin, MD</td>
</tr>
<tr>
<td>11:20–12:00 PM</td>
<td>Clinical Trial Participation in PAH: Patient Perspective</td>
<td>Clinical Research Patient Panel</td>
</tr>
<tr>
<td>12:00–1:00 PM</td>
<td>Lunch and Exhibits</td>
<td></td>
</tr>
<tr>
<td>1:00–1:40 PM</td>
<td>Updates in CTEPH (Medical and Surgical)</td>
<td>Talal I. Dahhan, MD, MSEd</td>
</tr>
<tr>
<td></td>
<td></td>
<td>John Carroll Haney, MD, MPH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Faculty Discussion Panel</td>
</tr>
<tr>
<td>1:40–2:25 PM</td>
<td>Precision Medicine in PAH</td>
<td>Anna Hemnes, MD</td>
</tr>
<tr>
<td>2:25–2:40 PM</td>
<td>Break and Exhibits</td>
<td></td>
</tr>
<tr>
<td>2:40–3:10 PM</td>
<td>What's New in Portopulmonary Hypertension?</td>
<td>H. James Ford, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kishan Parikh, MD</td>
</tr>
<tr>
<td>3:10–3:50 PM</td>
<td>Perplexing Pulmonary Hypertension Cases</td>
<td>UNC and Duke Fellows</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Faculty Panel</td>
</tr>
<tr>
<td>3:50–4:00 PM</td>
<td>Symposium Recap and Closing Remarks</td>
<td>H. James Ford, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Terry Fortin, MD</td>
</tr>
</tbody>
</table>

Please note: Invited faculty and program are subject to change without notice.
Course overview

The field of pulmonary arterial hypertension is a rapidly developing one, with multiple new treatments introduced in the last 25 years. This has created a steep learning curve for pulmonologists and cardiologists treating this disease, as well as primary care physicians who must remain mindful to consider the diagnosis in their patients. We seek to enhance the knowledge base of these physicians keeping them up to date on the evolving body of knowledge on pulmonary vascular disease. This dynamic state of the field serves to perpetuate a gap in regard to the knowledge of appropriate diagnostic procedures, proper treatment choices, and timing in advancement of care to pulmonary hypertension specialty centers. It is imperative that those treating this specialized disease have a thoroughly grounded knowledge of the appropriate work up, treatment, and care of the PAH patient.

The ACCP, AHA, ERS/ESC and WHO have convened on multiple occasions to develop consensus guidelines for the diagnosis and treatment of PAH. These guidelines have been published in prominent medical journals and presented at national meetings, thus exposing thousands of practitioners to these standardized approaches and promoting appropriate, structured care paradigms. The 11th Annual NC Research Triangle Pulmonary Hypertension Symposium will reinforce the current diagnostic and management guidelines of PAH put forth by the 6th World Symposium on Pulmonary Hypertension in 2018, as well as updates from subsequent national and international conferences. In addition, there will be a focus on the different subgroups of Pulmonary Hypertension, covering the diagnosis, management, and treatment for patients with WHO group 2-5 PH. Information about clinical trials, precision medicine, and challenging and nuanced presentations of PH will also be provided. It will provide a plentiful forum for questions and discussion, providing reinforcement of appropriate care practices and availability of regional referral centers.

Target audience

This program is designed to meet the continuing education (CE) needs of pulmonologists, cardiologists, nurses, pharmacists, and other allied healthcare professionals involved in the treatment of pulmonary hypertension.

Learning objectives:

- Describe classification of Pulmonary Hypertension, according to the World Symposium classifications and including updates from the 6th World Symposium, as well as the treatment options with respect to PAH-specific therapies.
- Recognize and distinguish similar disease processes that may or may not respond to Pulmonary Arterial Hypertension specific therapy.
- Identify various PH subtypes and understand their diagnosis and clinical course, particularly PH associated with hematologic disorders and portopulmonary hypertension.
- Risk stratify patients with pulmonary hypertension for surgical and procedural risk based upon disease severity and procedure type.
- Recognize the importance of right ventricular function and adaptation to the increased afterload seen in PAH. Understand that future therapies may directly target RV function and adaptability.
- Identify the role of clinical trials in the development of new PAH therapies, with a particular appreciation of the patient perspective as a clinical trial subject.
- Recognize the importance of nonpharmacologic interventions such as cardiac/pulmonary rehab.
- Describe the importance of screening for CTEPH and referral for definitive therapy, as well as gain knowledge on new developments in the field of CTEPH.
- Express how the evolving field of precision medicine applies to the current and future state of PAH diagnosis and treatment.

Sponsored by:

Duke Health

In collaboration with:

The Pulmonary Hypertension Association recognizes Duke University and University of North Carolina’s 11th Annual North Carolina Research Triangle Pulmonary Hypertension Symposium as a Building Medical Education in PH event.